Rapid nongenomic effects of aldosterone on human forearm vasculature

Hypertension

Volumn 42, Issue 2, 2003, Pages 156-160

  Schmidt, Bernhard M W ^b   Oehmer, Sebastian ^b   Delles, Christian ^b   Bratke, Renate ^b   Schneider, Markus P ^b   Klingbeil, Arnfried ^b   Fleischmann, Erwin H ^b   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NONE

Author keywords

Aldosterone; Endothelium; Hypertension, essential; Vasculature

Indexed keywords

ACETYLCHOLINE; ALDOSTERONE; N(G) METHYLARGININE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PLACEBO; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; ATTENUATION; BLOOD FLOWMETRY; BRACHIAL ARTERY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ENDOTHELIUM; FOREARM; FOREARM BLOOD FLOW; HUMAN; HYPERTENSION; INFUSION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; VASCULARIZATION; VASOCONSTRICTION; VEIN OCCLUSION PLETHYSMOGRAPHY; VOLUNTEER; BLOOD; BLOOD FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; GENOME; KINETICS; RANDOMIZED CONTROLLED TRIAL;

ACETYLCHOLINE; ADULT; ALDOSTERONE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOREARM; GENOME; HUMANS; KINETICS; MALE; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; PHENYLEPHRINE; REGIONAL BLOOD FLOW; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0043268703     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000083298.23119.16     Document Type: Article

References (21)

1. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet. 1999;353:40.
2. Schmidt BMW, Schmieder RE. Aldosterone induced cardiac damage. Am J Hypertens 2003;16:80-86.
3. Funder J. Non-genomic actions of aldosterone: role in hypertension. Curr Opin Nephrol Hypertens. 2001;10:227-230.
4. Falkenstein E, Tillmann H-C, Christ M, Feuring M, Wehling M. Multiple actions of steroid hormones: a focus on rapid, nongenomic effects. Pharmacol Rev. 2000;52:513-555.
5. Christ M, Sippel K, Eisen C, Wehling M. Non-classical receptors for aldosterone in plasma membranes from pig kidneys. Mol Cell Endocrinol. 1994;99:R31-R34.
6. Christ M, Eisen C, Aktas J, Theisen K, Wehling M. The inositol-1, 4, 5-triphosphate system is involved in rapid nongenomic effects of aldosterone in human mononuclear leukocytes. J Clin Endocrinol Metab. 1993;77:1452-1457.
7. Christ M, Eisen C, Meyer C, Theisen K, Wehling M. Immediate effects of aldosterone on diacylglycerol production and protein kinase C translocation in vascular smooth muscle cells. Biochem Biophys Res Commun. 1995;213:123-129.
8. Wehling M, Ulsenheimer A, Schneider M, Neylon C, Christ M. Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle and endothelial cells: subcellular localization of calcium release by single cell imaging. Biochem Biophys Res Commun. 1994;204:475-481.
9. Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JW. Nongenomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res. 1995;76:973-979.
10. Christ M, Günther A, Heck M, Schmidt BMW, Falkenstein E, Wehling M. Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells. Circulation. 1999;99:1485-1491.
11. Klein K, Henk W. Klinisch-experimentelle Untersuchungen über den Einfluß von Aldosteron auf Hämodynamik und Gerinnung. Zeitschrift für Kreislaufforschung 1963;52:40-53.
12. Wehling M, Spes CH, Win N, Janson C, Schmidt BMW, Theisen K, Christ M. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab. 1998;83:3517-3522.
13. Schmidt BMW, Montealegre A, Janson CP, Martin N, Scherhag A, Feuring M, Christ M. Wehling M. Short term cardiovascular effects of aldosterone in healthy male volunteers. J Clin Endocrinol Metab. 1999;84:3528-3533.
14. Schmidt BMW, Georgens AC, Martin N, Tillmann H-C, Janson CP, Scherhag A, Feuring M, Christ M, Wehling, M. Interaction of rapid, nongenomic cardiovascular aldosterone effects with the adrenergic system. J Clin Endocrinol Metab. 2001;86:761-767.
15. Barbato JC, Mulrow PJ, Shapiro JL, Franco-Saenz R. Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension. 2002;40:130-135.
16. Arami S, Kohagura H, Xu HL, Abe T, Takeuchi K, Ito S. Direct vasoconstrictor action of aldosterone in the glomerular microcirculation. J Hypertens. 2002;20:S198. Abstract.
17. John S, Delles C, Jacobi J, Schlaich MP, Schneider M, Schmitz G, Schmieder RE. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol. 2001;37:1351-1358.
18. Lösel RM, Feuring M, Falkenstein E, Wehling M. Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids, 2002;67:493-498.
19. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C. Myocardial production of aldosterone and corticosterone in the rat, Physiological regulation. J Biol Chem. 1998;273:4883-4891.
20. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;269:24316-24320.
21. Young MJ, Clyne CD, Cole TJ, Funder JW. Cardiac steroidogenesis in the normal and failing human heart. J Clin Endocrinol Metab. 2001;86:5121-5126.